Compugen (NASDAQ:CGEN) and Prenetics Global (NASDAQ:PRE) Financial Comparison

Prenetics Global (NASDAQ:PRE) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Prenetics Global and Compugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-61.33%	-19.61%	-15.33%
Compugen	47.97%	47.72%	27.51%

Risk & Volatility

Prenetics Global has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500.

Institutional & Insider Ownership

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Prenetics Global and Compugen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39 million	3.71	-$37.71 million	($4.02)	-5.06
Compugen	$72.76 million	3.52	$35.34 million	$0.37	7.31

Compugen has lower revenue, but higher earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Prenetics Global and Compugen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1	0	3	0	2.50
Compugen	1	0	3	1	2.80

Prenetics Global presently has a consensus price target of $32.33, suggesting a potential upside of 59.00%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 84.84%. Given Compugen’s stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than Prenetics Global.

Summary

Compugen beats Prenetics Global on 11 of the 14 factors compared between the two stocks.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.